Article Data

  • Views 2138
  • Dowloads 158

Original Research

Open Access

Overexpression of HIC1 plays a protective effect on renal cell injury caused by lipopolysaccharide by inhibiting IL-6/STAT3 pathway

  • Xiang Yang1
  • Jianfeng Gong1
  • Xiaosheng Cai2
  • Youjun Yuan2

1Department of Intensive care unit 2, Qingyuan People's Hospital, 511518 Qingyuan, Guangdong, China

2Department of Emergency, Wenzhou Central Hospital, 325000 Wenzhou, Zhejiang, China

DOI: 10.22514/sv.2022.016 Vol.18,Issue 2,March 2022 pp.147-153

Submitted: 30 September 2021 Accepted: 14 December 2021

Published: 08 March 2022

*Corresponding Author(s): Youjun Yuan E-mail: you_junyuan@163.com

Abstract

Sepsis is a life-threatening condition that can even occur due to an infection. Systemic inflammatory response syndrome acts a pivotal role in acute kidney injury (AKI). Although great advancements have been achieved for treating sepsis-induced AKI, its prognosis and pathophysiology remain unclear. In order to gain insights into the relevant role of hypermethylated in cancer 1 (HIC1) in AKI, a cellular model of AKI caused by sepsis was performed in lipopolysaccharide (LPS)-treated human kidney 2 (HK-2) cell line. The overexpression vector pcDNA3.1-HIC1 was transfected into HK-2 cell line to examine the effects of HIC1 on LPS-treated HK-2 cell line. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR), western blot and enzyme-linked immunosorbent assay (ELISA) assays were performed to examine the alterations in the expression levels of HIC1, cell apoptosis, or inflammation-related biomarkers. The apoptotic rate of HK-2 cell line was measured by flow cytometry. This study suggested that LPS treatment downregulated HIC1 and inhibited HK-2 cell viability, whereas HIC1 overexpressing reversed these effects. Importantly, HIC1 has a protective effect on LPS-induced cellular apoptosis and inflammatory response. Moreover, overexpression of HIC1 suppressed the LPS-induced activation of IL-6/STAT3 signaling pathway in HK-2 cell line. HIC1 protects HK-2 cell line against LPS-induced damage, which was partly through the inhibition of IL-6/STAT3 signaling pathways.


Keywords

Sepsis; Renal cell injury; HIC1 cell line; IL-6/STAT3; LPS


Cite and Share

Xiang Yang,Jianfeng Gong,Xiaosheng Cai,Youjun Yuan. Overexpression of HIC1 plays a protective effect on renal cell injury caused by lipopolysaccharide by inhibiting IL-6/STAT3 pathway. Signa Vitae. 2022. 18(2);147-153.

References

[1] Arina P, Singer M. Pathophysiology of sepsis. Current Opinion in Anaesthesiology. 2021; 34: 77–84.

[2] Schlapbach LJ, Trück J, Roger T. The immunology of sepsis—understanding host susceptibility, pathogenesis of disease, and avenues for future treatment. Frontiers in Immunology. 2020; 11: 1263.

[3] Mayeux PR, MacMillan-Crow LA. Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury. Pharmacology & Therapeutics. 2012; 134: 139–155.

[4] Gonsalez SR, Cortês AL, Silva RCD, Lowe J, Prieto MC, Silva Lara LD. Acute kidney injury overview: from basic findings to new prevention and therapy strategies. Pharmacology & Therapeutics. 2019; 200: 1–12.

[5] Zarjou A, Agarwal A. Sepsis and acute kidney injury. Journal of the American Society of Nephrology. 2011; 22: 999–1006.

[6] White LE, Hassoun HT. Inflammatory mechanisms of organ crosstalk during ischemic acute kidney injury. International Journal of Nephrology. 2012; 2012: 505197.

[7] Tan RZ, Wang C, Deng C, Zhong X, Yan Y, Luo Y, et al. Quercetin protects against cisplatin‐induced acute kidney injury by inhibiting Mincle/Syk/NF-κB signaling maintained macrophage inflammation. Phytotherapy Research. 2020; 34: 139–152.

[8] Inagi R. Endoplasmic reticulum stress as a progression factor for kidney injury. Current Opinion in Pharmacology. 2010; 10: 156–165.

[9] Gomez H, Ince C, De Backer D, Pickkers P, Payen D, Hotchkiss J, et al. A unified theory of sepsis-induced acute kidney injury inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2014; 41: 3–11.

[10] Fleuriel C, Touka M, Boulay G, Guérardel C, Rood BR, Leprince D. HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. The International Journal of Biochemistry & Cell Biology. 2009; 41: 26–33.

[11] Briones VR, Chen S, Riegel AT, Lechleider RJ. Mechanism of fibroblast growth factor-binding protein 1 repression by TGF-beta. Biochemical and Biophysical Research Communications. 2006; 345: 595–601.

[12] Tseng RC, Lee CC, Hsu HS, Tzao C, Wang YC. Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia. 2009; 11: 763–770.

[13] Kim MK, Jeon BN, Koh DI, Kim KS, Park SY, Yun CO, et al. Regulation of the cyclin-dependent kinase inhibitor 1A Gene (CDKN1A) by the repressor BOZF1 through inhibition of p53 acetylation and transcription factor Sp1 binding. Journal of Biological Chemistry. 2013; 288: 7053–7064.

[14] Hu B, Zhang K, Li S, Li H, Yan Z, Huang L, et al. HIC1 attenuates invasion and metastasis by inhibiting the IL-6/STAT3 signalling pathway in human pancreatic cancer. Cancer Letters. 2016; 376: 387–398.

[15] Zeng S, Wu X, Chen X, Xu H, Zhang T, Xu Y. Hypermethylated in cancer 1 (HIC1) mediates high glucose induced ROS accumulation in renal tubular epithelial cells by epigenetically repressing SIRT1 transcription. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2018; 1861: 917–927.

[16] Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene. 2000; 19: 2638–2644.

[17] Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Research. 2008; 18: 443–451.

[18] Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Science. 2018; 27: 1984–2009.

[19] Sirkisoon SR, Carpenter RL, Rimkus T, Anderson A, Harrison A, Lange AM, et al. Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene. 2018; 37: 2502–2514.

[20] Unver N, McAllister F. IL-6 family cytokines: key inflammatory mediators as biomarkers and potential therapeutic targets. Cytokine & Growth Factor Reviews. 2018; 41: 10–17.

[21] Wang L, Cao L, Wang H, Liu B, Zhang Q, Meng Z, et al. Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway. Oncotarget. 2017; 8: 76116–76128.

[22] Ning F, Zheng H, Tian H, Wang T, Hao D, Han S, et al. Research on effect of adiponectin on sepsis-induced lung injury in rats through IL-6/STAT3 signaling pathway. Panminerva Medica. 2020; 62: 184–186.

[23] Li Y, Yao M, Wu T, Zhang L, Wang Y, Chen L, et al. Loss of hypermethylated in cancer 1 (HIC1) promotes lung cancer progression. Cellular Signalling. 2019; 53: 162–169.

[24] Pianta TJ, Gobe GC, Owens EP, Endre ZH. Overview of pathophysiology of acute kidney injury: human evidence, mechanisms, pathological correlations and biomarkers and animal models. In: Waikar S., Murray P., Singh A. (eds) Core Concepts in Acute Kidney Injury (pp. 45–67). 1st edn. Springer: New York, NY. 2018.

[25] Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005; 123: 437–448.

[26] Liao Y, Guo S, Chen Y, Cao D, Xu H, Yang C, et al. VSIG4 expression on macrophages facilitates lung cancer development. Laboratory Investi-gation. 2014; 94: 706–715.

[27] Lin YM, Wang CM, Jeng JC, Leprince D, Shih HM. HIC1 interacts with and modulates the activity of STAT3. Cell Cycle. 2013; 12: 2266–2276.

[28] Wu W, Zhang L, Lin J, Huang H, Shi B, Lin X, et al. Hypermethylation of the HIC1 promoter and aberrant expression of HIC1/SIRT1 contribute to the development of thyroid papillary carcinoma. Oncotarget. 2016; 7: 84416–84427.

[29] Kuwabara T, Imajoh-Ohmi S. LPS-induced apoptosis is dependent upon mitochondrial dysfunction. Apoptosis. 2004; 9: 467–474.

[30] Liu S, Gallo DJ, Green AM, Williams DL, Gong X, Shapiro RA, et al. Role of toll-like receptors in changes in gene expression and NF-kappa B activation in mouse hepatocytes stimulated with lipopolysaccharide. Infection and Immunity. 2002; 70: 3433–3442.

[31] Lin M, Rikihisa Y. Ehrlichia chaffeensisdownregulates surface Toll-like receptors 2/4, CD14 and transcription factors PU.1 and inhibits lipopolysaccharide activation of NF-kappa B, ERK 1/2 and p38 MAPK in host monocytes. Cellular Microbiology. 2004; 6: 175–186.

[32] Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell. 2011; 19: 429–431.

[33] Gupta S, Jain A, Syed SN, Snodgrass RG, Pflüger-Müller B, Leisegang MS, et al. IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors. Oncoimmunology. 2018; 7: e1494110.

[34] Ranganathan P, Jayakumar C, Ramesh G. Proximal tubule-specific overexpression of netrin-1 suppresses acute kidney injury-induced interstitial fibrosis and glomerulosclerosis through suppression of IL-6/STAT3 signaling. American Journal of Physiology-Renal Physiology. 2013; 304: F1054–F1065.

[35] Xiao Y, Yang N, Zhang Q, Wang Y, Yang S, Liu Z. Pentraxin 3 inhibits acute renal injury-induced interstitial fibrosis through suppression of IL-6/Stat3 pathway. Inflammation. 2014; 37: 1895–1901.

[36] Laudisi F, Cherubini F, Monteleone G, Stolfi C. STAT3 interactors as potential therapeutic targets for cancer treatment. International Journal of Molecular Sciences. 2018; 19: 1787.

[37] Wang X, Wang Y, Xiao G, Wang J, Zu L, Hao M, et al. Hypermethylated in cancer 1(HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway. Oncotarget. 2016; 7: 30350–30364.

[38] Sun X, Qu Q, Lao Y, Zhang M, Yin X, Zhu H, et al. Tumor suppressor HIC1 is synergistically compromised by cancer-associated fibroblasts and tumor cells through the IL-6/pSTAT3 axis in breast cancer. BMC Cancer. 2019; 19: 1180.



Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top